Evaluation of Changes in the Expression Profile of mRNA and Proteinencoding Adiponectin in Ishikawa Cell Line under the Influence of Cisplatin - Preliminary Report.

Robert Kiełabsiński, Przemysław Kieszkowski, Beniamin O Grabarek, Dariusz Boroń
Author Information
  1. Robert Kiełabsiński: Department of Obstetrics & Gynaecology ward, Health Center in Mikołów, Mikołów, Poland
  2. Przemysław Kieszkowski: Voivodeship Specialist Hospital in Wloclawek, Wloclawek, Poland
  3. Beniamin O Grabarek: Department of Histology, Cytophysiology and Embryology, Faculty of Medicine, University of Technology, Zabrze, Poland
  4. Dariusz Boroń: Department of Histology, Cytophysiology and Embryology, Faculty of Medicine, University of Technology, Zabrze, Poland

Abstract

BACKGROUND: A reduced concentration of Adiponectin is considered as an independent factor of the risk of inducing endometrial cancer. Cisplatin is a drug used in the therapy of this type of neoplasm. However, knowledge of the effects of Cisplatin on the Adiponectin level is still limited.
OBJECTIVE: The purpose of this study was to assess the impact of Cisplatin depending on the concentration and time of exposition of the cells to the drug on the Adiponectin level in the endometrial cancer cell line.
METHODS: Cells of endometrial cancer cell line Ishikawa were exposed for 12,24 and 48 hour periods to Cisplatin with the following concentrations: 2.5μM, 5μM, 10μM. The changes in the expression profile of Adiponectin were compared to the RtqPCR reaction and ELISA test. The STATISTICA 13.0 PL program was used for statistical analysis (p<0.05).
RESULTS: In the culture without the drug, the concentration of Adiponectin was statistically lower than in the cell culture incubated with the drug. Changes on the mRNA level seem to be more specific than on the protein level, although in both cases, the same trend in the expression changes was noted.
DISCUSSION: The longer the time of exposition of the cells to the drug, the expression of mRNA, and the Adiponectin protein increased. Changes in the expression profile were characterized statistically (p<0.05).
CONCLUSION: Cisplatin, in a noticeable way, changes the expression profile of Adiponectin. Molecular analysis indicated that in the case of endometrial cancer therapy should be implemented with a concentration of no less than 5 μM.

Keywords

References

  1. J Clin Oncol. 2006 Jan 1;24(1):36-44 [PMID: 16330675]
  2. Int J Stem Cells. 2014 Nov;7(2):118-26 [PMID: 25473449]
  3. J Nephrol. 2018 Feb;31(1):15-25 [PMID: 28382507]
  4. J Mol Med (Berl). 2015 Dec;93(12):1327-39 [PMID: 26153548]
  5. Hum Cell. 1996 Jun;9(2):109-16 [PMID: 9183638]
  6. Biol Pharm Bull. 2015;38(7):961-5 [PMID: 26133703]
  7. Eur J Endocrinol. 2005 Jan;152(1):113-8 [PMID: 15762194]
  8. J Transl Med. 2012 Mar 06;10:38 [PMID: 22394685]
  9. Gynecol Endocrinol. 2020 Jan;36(1):66-71 [PMID: 31242787]
  10. J Mol Cell Biol. 2016 Apr;8(2):101-9 [PMID: 26993044]
  11. Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2476-81 [PMID: 14983034]
  12. Int J Mol Sci. 2019 Feb 15;20(4): [PMID: 30781341]
  13. Rom J Morphol Embryol. 2018;59(4):1165-1172 [PMID: 30845297]
  14. Zhonghua Fu Chan Ke Za Zhi. 2018 Aug 25;53(8):554-560 [PMID: 30138966]
  15. Nat Metab. 2019 Mar;1(3):334-339 [PMID: 32661510]
  16. Int J Mol Sci. 2019 Mar 08;20(5): [PMID: 30857216]
  17. Front Oncol. 2018 Feb 05;8:15 [PMID: 29459886]
  18. Int J Gynaecol Obstet. 2019 Apr;145(1):34-39 [PMID: 30702161]
  19. Wiley Interdiscip Rev Syst Biol Med. 2018 Jan;10(1): [PMID: 28857478]
  20. Int J Cancer. 2015 Oct 15;137(8):1967-78 [PMID: 25899043]
  21. J Clin Endocrinol Metab. 2007 Mar;92(3):1041-8 [PMID: 17192291]
  22. Am J Gastroenterol. 2006 Nov;101(11):2629-40 [PMID: 16952281]
  23. Nat Rev Gastroenterol Hepatol. 2018 Jun;15(6):349-364 [PMID: 29740166]
  24. Oncol Lett. 2016 Sep;12(3):2092-2098 [PMID: 27625708]
  25. Mol Cancer Ther. 2011 Dec;10(12):2234-43 [PMID: 21980131]
  26. Oncotarget. 2016 Jun 14;7(24):35832-35842 [PMID: 27127883]
  27. Am J Obstet Gynecol. 1992 Nov;167(5):1317-25 [PMID: 1442985]
  28. Cell Commun Signal. 2016 Jan 12;14:4 [PMID: 26759169]
  29. J Clin Invest. 2003 Jul;112(1):91-100 [PMID: 12840063]
  30. Circ Res. 2004 Mar 5;94(4):e27-31 [PMID: 14752031]

MeSH Term

Adiponectin
Antineoplastic Agents
Cell Line, Tumor
Cisplatin
Dose-Response Relationship, Drug
Endometrial Neoplasms
Female
Gene Expression
Humans
RNA, Messenger

Chemicals

Adiponectin
Antineoplastic Agents
RNA, Messenger
Cisplatin

Word Cloud

Created with Highcharts 10.0.0adiponectinendometrialcancerdrugexpressionconcentrationcisplatinlevelcellCisplatinlineIshikawachangesprofileChangesmRNAusedtherapytimeexpositioncells5μManalysisp<005culturestatisticallyproteinAdiponectinBACKGROUND:reducedconsideredindependentfactorriskinducingtypeneoplasmHoweverknowledgeeffectsstilllimitedOBJECTIVE:purposestudyassessimpactdependingMETHODS:Cellsexposed122448hourperiodsfollowingconcentrations:210μMcomparedRtqPCRreactionELISAtestSTATISTICA130PLprogramstatisticalRESULTS:withoutlowerincubatedseemspecificalthoughcasestrendnotedDISCUSSION:longerincreasedcharacterizedCONCLUSION:noticeablewayMolecularindicatedcaseimplementedless5μMEvaluationExpressionProfileProteinencodingCellLineInfluence-PreliminaryReportmolecularmarker

Similar Articles

Cited By

No available data.